Impact of Frontline Treatment Strategies on Outcomes in Patients With Acute Myeloid Leukemia, Myelodysplasia‐Related
Cancer Reports · 2026-06 · 9 (6)
DOI: 10.1002/cnr2.70607 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 21.06.2026. Verfasst von Yi Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Medical and Health Research Project of Zhejiang Province.
Abstract (Originalsprache)
Background
The 5th edition of the World Health Organization (WHO) classification updated the term for acute myeloid leukemia with myelodysplasia‐related changes (AML‐MRC) to acute myeloid leukemia, myelodysplasia‐related (AML‐MR), along with new diagnostic criteria. However, the clinical prognostic outcomes of patients diagnosed with AML‐MR based on the new WHO definition remain poorly defined, and the optimal frontline treatment strategy for this patient population has not been fully clarified.
Aims
This study aimed to compare the clinical efficacy and survival outcomes of three mainstream frontline treatment regimens for newly diagnosed AML‐MR patients and identify independent prognostic factors affecting patient survival. Methods and Results We collected data from 142 patients with newly diagnosed AML‐MR and divided them into three cohorts depending on different frontline therapies: low‐intensity chemotherapy (LIC), intensive chemotherapy (IC), and venetoclax plus hypomethylating agent (VEN/HMA). The overall response rate in the VEN/HMA cohort was higher than in the LIC or IC cohort (VEN/HMA vs. LIC, 72.7% vs. 42.1%, p = 0.010; VEN/HMA vs. IC, 72.7% vs. 54.3%, p = 0.049). Event‐free survival (EFS) in the LIC cohort was inferior to that in the IC cohort (median 2.5 vs. 4.8 months, p = 0.037) or VEN/HMA cohort (median 2.5 vs. 6.4 months, p = 0.006). The overall survival (OS) in the LIC cohort was inferior to that in the IC cohort (median 11.9 vs. 19.4 months, p = 0.009). No statistically significant differences in EFS or OS were observed between the IC and VEN/HMA cohorts. Multivariate analyses showed that prior HMA exposure and frontline LIC therapy were associated with inferior EFS, and allogeneic hematopoietic stem cell transplantation was associated with better EFS and OS.
Conclusion
Our study suggests that in patients with AML‐MR, frontline therapy with VEN/HMA or IC improves outcomes compared with LIC. Allogeneic hematopoietic stem cell transplantation is encouraged for all eligible patients with AML‐MR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
- Institute of Hematology, Zhejiang University, Hangzhou, China.
- Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.
- The Affiliated Li Huili Hospital of Ningbo University, Ningbo, China.
ORCID-Profile: Yi Li, Dian Jin, Jingsong He, Zhen Cai
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Medical and Health Research Project of Zhejiang Province
Zitieren
APA
Li, Y., Jin, D., Fang, P., Meng, X., He, D., Lin, J., Le, J., Shu, W., Yang, Q., He, J., & Cai, Z. (2026). Impact of Frontline Treatment Strategies on Outcomes in Patients With Acute Myeloid Leukemia, Myelodysplasia‐Related. Cancer Reports, 9(6). https://doi.org/10.1002/cnr2.70607
Vancouver
Li Y, Jin D, Fang P, Meng X, He D, Lin J, et al. Impact of Frontline Treatment Strategies on Outcomes in Patients With Acute Myeloid Leukemia, Myelodysplasia‐Related. Cancer Reports. 2026;9(6). doi:10.1002/cnr2.70607
BibTeX
@article{Li2026,
author = {Li, Yi and Jin, Dian and Fang, Peiying and Meng, Xinyi and He, Donghua and Lin, Jintao and Le, Jing and Shu, Wenxiu and Yang, Qianqian and He, Jingsong and Cai, Zhen},
title = {Impact of Frontline Treatment Strategies on Outcomes in Patients With Acute Myeloid Leukemia, Myelodysplasia‐Related},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {6},
doi = {10.1002/cnr2.70607}
}
EUVIMED